BGIM
SRPT icon

Brandywine Global Investment Management’s Sarepta Therapeutics SRPT Stock Holding History

Brandywine Global Investment Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-24,203
Closed -$414K – 649
2025
Q2 		$414K Sell
24,203
-150,378
-86% -$6.42M ﹤0.01% 553
2025
Q1 		$11.1M Sell
174,581
-11,395
-6% -$1.2M 0.08% 238
2024
Q4 		$22.6M Buy
+185,976
New +$22.8M 0.16% 154

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Brandywine Global Investment Management's SRPT Position: Q3 2025 in Review

Brandywine Global Investment Management sold out of Sarepta Therapeutics (SRPT) in Q3 2025, closing a stake of 24,203 shares — an estimated $414K sold.

Brandywine Global Investment Management first reported a position in SRPT in Q4 2024 and held it in 3 quarters. The position peaked at $22.6M in Q4 2024. 319 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Brandywine Global Investment Management reported no remaining Sarepta Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Brandywine Global Investment Management sold 24,203 Sarepta Therapeutics shares in Q3 2025, an estimated $414K.
  • Brandywine Global Investment Management first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 3 quarters.
  • Brandywine Global Investment Management's Sarepta Therapeutics position peaked at $22.6M in Q4 2024.
  • 319 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Brandywine Global Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.